2. Vitamin D Related/Nuclear Receptor
  3. Nuclear Hormone Receptor 4A/NR4A
  4. IP7e

IP7e is a potent, brain-penetrant and orally active Nurr1 activator with an EC50 value of 3.9 nM.

For research use only. We do not sell to patients.

IP7e Chemical Structure

IP7e Chemical Structure

CAS No. : 500164-74-9

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 385 In-stock
Solution
10 mM * 1 mL in DMSO USD 385 In-stock
Solid
5 mg USD 350 In-stock
10 mg USD 550 In-stock
25 mg USD 940 In-stock
50 mg USD 1350 In-stock
100 mg USD 1850 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

IP7e Related Antibodies

Top Publications Citing Use of Products

View All Nuclear Hormone Receptor 4A/NR4A Isoform Specific Products:

View All Isoforms
Nurr1/NR4A2 Nur77/NR4A1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

IP7e is a potent, brain-penetrant and orally active Nurr1 activator with an EC50 value of 3.9 nM[1].

IC50 & Target

Nurr1/NR4A2

 

In Vivo

IP7e (Isoxazolo-pyridinone 7e; 10 mg/kg; oral gavage; twice a day) preventive treatment reduces the incidence and the severity of a MS murine model, i.e. experimental autoimmune encephalomyelitis (EAE). IP7e attenuates inflammation and neurodegeneration in spinal cords of EAE mice by an NF-kB pathway-dependent process[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female C57BL/6J mice (6-8 week-old) with experimental autoimmune encephalomyelitis (EAE)[2].
Dosage: 10 mg/kg
Administration: Oral gavage; twice a day; preventive administration (before the disease onset) from 7 to 23 d.p.i. and therapeutic (after the disease onset) from 21 to 36 d.p.i.
Result: Preventive administration delayed the onset and reduces the incidence and severity of EAE, and decreased neuroinflammatory and histopathological alterations in the spinal cord of treated EAE mice. On the contrary, the course of EAE was not influenced by the therapeutic administration.
Molecular Weight

390.43

Formula

C23H22N2O4
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C1C2=C(C=C(C3=CC=C(COCCOC)C=C3)N1C)ON=C2C4=CC=CC=C4
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (256.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5613 mL 12.8064 mL 25.6128 mL
5 mM 0.5123 mL 2.5613 mL 5.1226 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.65%

SDS (393 KB)

COA (245 KB) LCMS (96 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5613 mL 12.8064 mL 25.6128 mL 64.0320 mL
5 mM 0.5123 mL 2.5613 mL 5.1226 mL 12.8064 mL
10 mM 0.2561 mL 1.2806 mL 2.5613 mL 6.4032 mL
15 mM 0.1708 mL 0.8538 mL 1.7075 mL 4.2688 mL
20 mM 0.1281 mL 0.6403 mL 1.2806 mL 3.2016 mL
25 mM 0.1025 mL 0.5123 mL 1.0245 mL 2.5613 mL
30 mM 0.0854 mL 0.4269 mL 0.8538 mL 2.1344 mL
40 mM 0.0640 mL 0.3202 mL 0.6403 mL 1.6008 mL
50 mM 0.0512 mL 0.2561 mL 0.5123 mL 1.2806 mL
60 mM 0.0427 mL 0.2134 mL 0.4269 mL 1.0672 mL
80 mM 0.0320 mL 0.1601 mL 0.3202 mL 0.8004 mL
100 mM 0.0256 mL 0.1281 mL 0.2561 mL 0.6403 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

IP7e Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

IP7e500164-74-9Nuclear Hormone Receptor 4A/NR4ANerve Growth Factor IB-like ReceptorNurr1orallybrain-penetrantNF-kBInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
IP7e
Cat. No.:
HY-110274
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.